Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty
PHASE3CompletedINTERVENTIONAL
Enrollment
3,426
Participants
Timeline
Start Date
February 24, 2013
Primary Completion Date
July 31, 2016
Study Completion Date
July 31, 2016
Conditions
Venous Thromboembolism
Interventions
DRUG
rivaroxaban and ASA
Trial Locations (1)
B3H 3A7
Capital Health, Halifax
All Listed Sponsors
collaborator
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
lead
David Anderson
OTHER
NCT01720108 - Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty | Biotech Hunter | Biotech Hunter